James N. Topper Acquires 8,584 Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper acquired 8,584 shares of NewAmsterdam Pharma stock in a transaction dated Monday, June 16th. The shares were bought at an average cost of $19.50 per share, for a total transaction of $167,388.00. Following the completion of the purchase, the director now directly owns 3,022,153 shares of the company’s stock, valued at approximately $58,931,983.50. The trade was a 0.28% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS opened at $18.20 on Thursday. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $27.29. The firm has a 50-day moving average of $18.39 and a 200 day moving average of $20.82. The stock has a market cap of $2.04 billion, a P/E ratio of -9.68 and a beta of -0.03.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The company had revenue of $2.98 million during the quarter, compared to analysts’ expectations of $1.46 million. Research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Cantor Fitzgerald began coverage on NewAmsterdam Pharma in a research note on Wednesday, June 4th. They issued an “overweight” rating and a $42.00 price target on the stock. Citigroup began coverage on shares of NewAmsterdam Pharma in a research report on Tuesday. They set a “buy” rating and a $42.00 price target for the company. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Friday, May 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Finally, Stifel Nicolaus started coverage on NewAmsterdam Pharma in a research note on Tuesday, June 10th. They issued a “buy” rating and a $44.00 price target for the company. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $42.89.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NAMS. Mirae Asset Global Investments Co. Ltd. raised its holdings in NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company’s stock worth $80,000 after acquiring an additional 596 shares during the last quarter. Quarry LP purchased a new stake in shares of NewAmsterdam Pharma during the first quarter valued at $25,000. GF Fund Management CO. LTD. bought a new stake in NewAmsterdam Pharma in the 4th quarter worth about $50,000. National Bank of Canada FI purchased a new position in NewAmsterdam Pharma in the 4th quarter worth about $51,000. Finally, Geode Capital Management LLC raised its position in NewAmsterdam Pharma by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 88,544 shares of the company’s stock worth $2,276,000 after buying an additional 2,222 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.